Loading...
 

Volume 32, Issue 3, September 2021




Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2021;32(3):264-72
Methotrexate-Related Liver Cirrhosis in Psoriatic Arthritis: A Case Report and Review of the Literature
Authors Information

1. Department of Pathophysiology, “Laiko” Hospital, School of Medicine, National and Kapodistrian University of Greece, Athens, Greece

2. First Department of Internal Medicine, “Laiko” Hospital, School of Medicine, National and Kapodistrian University of Greece, Athens, Greece

3. Department of Pathology, School of Medicine, National and Kapodistrian University of Greece, Athens, Greece

T Androutsakos, S Sakellariou, CG Gialouri, GE Fragoulis

References
  1. Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, et al. Methotrexate an old drug with new tricks. Int J Mol Sci 2019;20(20).
  2. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60(8):729-35.
  3. Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 2016;12(12):731-42.
  4. Chan ESL, Cronstein BN. Methotrexate how does it really work? Nat Rev Rheumatol 2010;6(3):175-8.
  5. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60(5):824-37.
  6. Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J, et al. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatol (United Kingdom) 2017;56(6):865-8.
  7. Saag KG, Gim GT, Patkar NM, Anuntiyo J, Finney C, Curtis J, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res 2008;59(6):762-84.
  8. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29(7):832-35.
  9. Chan ESL, Montesinos MC, Fernandez P, Desai A, Delano D, Yee H, et al. Adenosine A 2A receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol 2006;148(8):1144-55.
  10. Curtis JR, Beukelman T, Onofrei A, Greenberg JD, Kavanaugh A, Reed G, et al. Elevated liver enzyme tests among rheumatoid arthritis and psoriatic arthritis patients treated with methotrexate and/or leflunomide. Ann Rheum Dis 2011;69(1):43-7.
  11. Dirven L, Klarenbeek NB, van den Broek M, van Groenendael JH, de Sonnaville PB, Kerstens PJ, et al. Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy. Clin Rheumatol 2013;32(5):585-90.
  12. Salliot C, Van Der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research. Ann Rheum Dis 2009;68(7):1100-4.
  13. Whiting-O’Keefe QE, Fye KH, Sack KD, Strom BL. Methotrexate and histologic hepatic abnormalities: A meta-analysis. Ann Intern Med 1991;115(6 SUPPL. 2):61.
  14. Wilke WS, Biro JA, Segal AM. Methotrexate in the treatment of arthritis and connective tissue diseases. Cleve Clin J Med 1987;54(4):327-38.
  15. Fuhlbrigge RC, Özen S, Dedeoğlu F. Arthritis Care & Research. This article has been accepted for publication and undergone full peer review but has not been through the copyediting , typesetting , pagination and proofreading process which may lead to differences between this version and the. Published online 2016.
  16. Visser K, Van Der Heijde DMFM. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: A systematic review of the literature. Clin Exp Rheumatol 2009;27(6):1017-25.
  17. Roenigk  Jr. HH, Bergfeld WF, Jacques R St., Owens FJ, Hawk WA, Weinstein GD, et al. Evaluation of Possible Chronic Hepatotoxicity From Methotrexate for Psoriasis. Arch Dermatol 1971;102(6):250-61.
  18. Dahl MGC, Gregory MM, Scheuer PJ. Liver Damage due to Methotrexate in Patients with Psoriasis. Br Med J 1971;1(5750):625-30.
  19. Risteli J, Søgaard H, Oikarinen A, Risteli L, Karvonen J, Zachariae H. Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis. Br J Dermatol 1988 Sep;119(3):321-5.
  20. ariae H, Aslam HM, Bjerring P, Søgaard H, Zachariae E, Heickendorff L. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991;25(1 Pt 1):50-3.
  21. Nohlgård C, Rubio CA, Kock Y, Hammar H. Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis. J Am Acad Dermatol 1993;28(1):40-5.
  22. Boffa MJ, Chalmers RJG, Haboubi NY, Shomaf M, Mitchell DM. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: A reappraisal. Br J Dermatol 1995;133(5):774-8.
  23. Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ. Methotrexate hepatotoxicity in psoriatics: Report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996;10(6):369-75.
  24. Grismer LE, Gill SA, Harris MD. Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. J Clin Rheumatol 2001;7(4):224-7.
  25. Zachariae H, Heickendorff L, Søgaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: A 10-year follow-up. Br J Dermatol 2001;144(1):100-3.
  26. Wollina U, Ständer K, Barta U. Toxicity of methotrexate treatment in psoriasis arthritis - short- and long-term toxicity in 104 patients. Clin Rheumatol 2001;20(6):406-10.
  27. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology 2009;48(5):569-72.
  28. Laharie D, Seneschal J, Schaeverbeke T, Doutre MS, Longy-Boursier M, Pellegrin JL, Chabrun E, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: A case-control study. J Hepatol 2010;53(6):1035-40.
  29. Millward-Sadler GH, Ryan TJ. Methotrexate induced liver disease in psoriasis. Br J Dermatol. 1974 Jun;90(6):661-7.
  30. Barbero-Villares A, Mendoza J, Trapero-Marugan M, Gonzalez-Alvaro I, Daudén E, Gisbert J, et al. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients. Med Clin (Barc) 2011;137(14):637-9.
  31. Vandervoort EAM, Koehler EM, Nijsten T, Stricker BH, Hofman A, Janssen HLA, et al. Increased prevalence of advanced liver fibrosis in patients with psoriasis: A cross-sectional analysis from the rotterdam study. Acta Derm Venereol 2016;96(2):213-7.
  32. Talme T, Nikamo P, Rosenberg P, Ståhle M. Transient elastography may improve detection of liver fibrosis in psoriasis patients treated with methotrexate. Acta Derm Venereol 2017;97(8):952-4.
  33. García DS, Saturansky EI, Poncino D, Martínez-Artola Y, Rosenberg S, Abritta G, et al. “Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?” Ann Hepatol 2019;18(5):765-9.
  34. Maybury CM, Porter HF, Kloczko E, Duckworth M, Cotton A, Thornberry K, et al. Prevalence of Advanced Liver Fibrosis in Patients with Severe Psoriasis. JAMA Dermatology 2019;155(9):1028-32.
  35. Neema S, Banerjee D, Radhakrishnan S, Vasudevan B, Sinha P, Oberoi B. Use of Transient Elastography in Detection of Liver Fibrosis in Psoriasis Patients - A Cross- Sectional Study. Indian Dermatol Online J 2020;11(3):387-90.
  36. Honda H, Ikejima K, Hirose M, Yoshikawa M, Lang T, Enomoto N, et al. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002;36(1):12-21.
  37. O’Connor GT, Olmstead EM, Zug K, Baughman R, Beck J, Dunn J, et al. Detection of hepatotoxicity associated with methotrexate therapy for psoriasis. Arch Dermatol 1989;125(9):1209-17.
  38. Themido R, Loureiro M, Pecegueiro M, Brandão M, Campos MC. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol 1992;72(5):361-4.
  39. Zachariae H, Grunnet E, Sogaard H (1975) Liver biopsy in methotrexate treated psoriatics: a reevaluation. Acta Derm Venereol 1975;55(4):291-6.
  40. Nyfors A, Poulsen H. LIVER BIOPSIES FROM PSORIATICS RELATED TO METHOTREXATE THERAPY. 2. Findings before and after Methotrexate Therapy in 88 Patients. A Blind Study. Acta Pathol Microbiol Scand Sect A Pathol 1976;84 A(3):262-70.
  41. Zachariae H, Kragballe K, Søgaard H. Methotrexate induced liver cirrhosis: STUDIES INCLUDING SERIAL LIVER BIOPSIES DURING CONTINUED TREATMENT. Br J Dermatol 1980;102(4):407-12.
  42. Ashton RE, Millward-Sadler GH, White JE. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982;79(4):229-32.
  43. Lanse SB, Arnold GL, Gowans JDC, Kaplan MM. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis - An acceptable risk/benefit ratio. Dig Dis Sci 1985;30(2):104-9.
  44. Van De Kerkhof PCM, Hoefnagels WHL, Van Haelst UJGM, Mali JWH. Methotrexate maintenance therapy and liver damage in psoriasis. Clin Exp Dermatol 1985;10(3):194-200.
  45. Pestana A, Halprin KM, Taylor JR, Schiff ER, Esquenazi V, Comerford M, et al. Predictive value of HLA antigen for methotrexate-induced liver damage in patients with psoriasis. J Am Acad Dermatol 1985;12(1):26-9.
  46. Rosenberg P, Urwitz H, Johannesson A, Ros A, Lindholm J, Kinnman N, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46(6):1111-8.
  47. an M, Auerbach R, Feiner H, Holzman RS, Shupack J, Migdal P, et al. Evaluation of Possible Chronic Hepatotoxicity From Methotrexate for Psoriasis. Arch Dermatol 1989;125(9):613-8.
  48. ury CM, Jabbar-Lopez ZK, Wong T, Duckworth M, Cotton A, Thornberry K, et al. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. Br J Dermatol 2014;171:17-29.
  49. Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol 2018;36(1):21-8.
  50. Dal Bello G, Gisondi P, Idolazzi L, Girolomoni G. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. Rheumatol Ther 2020;7(2):271-85.
  51. Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol 2012;39(SUPPL. 89):24-8.
  52. Gottlieb AB, Dann F. Comorbidities in Patients with Psoriasis. Am J Med 2009;122(12):1-9.
  53. Labitigan M, Bahče-Altuntas A, Kremer JM, Reed G, Greenberg J, Jordan N, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res 2014;66(4):600-7.
  54. Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci 2018;19(1).
  55. Di Minno MND, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, et al. Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis. Arthritis Care Res 2013;65(1):141-7.
  56. Leite BF, Morimoto MA, Gomes C, Klemz B, Genaro P, Damasceno N, et al. Higher bodily adiposity, fat intake, and cholesterol serum levels are associated with higher disease activity in psoriatic arthritis patients: Is there a link among fat and skin and joint involvement? Lipids Health Dis 2020;19(1):1-10.
  57. Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N, et al. Obesity and psoriatic arthritis: From pathogenesis to clinical outcome and management. Rheumatol (United Kingdom) 2013;52(1):62-7.
  58. Nestle F, Kaplan D, Barker J. Review Article: Mechanisms of Disease Psoriasis. N Engl J Med 2009;361(5):496-509.
  59. Nikiphorou E, Fragoulis GE. Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review. Ther Adv Musculoskelet Dis 2018 Aug;10(8):157-67.
  60. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002;37:206-13.
  61. Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in liver cirrhosis. Int J Mol Sci 2017;18(7):1392.
  62. Ataseven H, Bahcecioglu IH, Kuzu N, Yalniz M, Celebi S, Erensoy A, et al. The levels of ghrelin, leptin, TNF-α, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators Inflamm 2006;2006:1-6.
  63. Bolukbas FF, Bolukbas C, Horoz M, Gumus M, Erdogan M, Zeyrek F, et al. Child-Pugh classification dependent alterations in serum leptin levels among cirrhotic patients: A case controlled study. BMC Gastroenterol 2004;4:1-6.
  64. McCullough AJ, Bugianesi E, Marchesini G, Kalhan SC. Gender-dependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology 1998;115(4):947-53.
  65. Onodera K, Kato A, Suzuki K. Serum leptin concentrations in liver cirrhosis: Relationship to the severity of liver dysfunction and their characteristic diurnal profiles. Hepatol Res 2001;21(3):205-12.
  66. Quintin E, Scoazec JY, Marotte H, Miossec P. Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther 2010;12(4).